z-logo
Premium
Wilhelm Fabry’s 1614 report on a giant condyloma of the penis
Author(s) -
Marx F.J.,
Karenberg A.
Publication year - 2012
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2011.10654.x
Subject(s) - medicine , eponym , penis , penile cancer , dermatology , surgery , physics , acoustics
Summary For many years it has been the work of Buschke and Löwenstein that has justified calling the exophytic, locally destructive tumour of the anogenital mucosal surface ‘giant condyloma of Buschke and Löwenstein’ or GCBL. In order to investigate the early history of this rare disease we examined the writings of the barber‐surgeon Wilhelm Fabry (1560–1634) who had a serious interest in dermatological disorders and their treatment. We analysed Fabry’s 600 Latin case reports and identified the case of a ‘monstrous penile tumour’. We then translated this text into English and compared it point by point with later publications. This was followed by a cursory review of surgical treatises from the 16th to the 18th centuries. In 1614 Fabry described and depicted a tumour of the penis; the clinical characteristics (gradual formation of a warty lesion, considerable size, invasive growth, absence of metastases) indicated it was a giant condyloma. His mention of the urethral fistulization enables discrimination from ‘common’ condylomata acuminata, and the survival period of 10 years after amputation allows exclusion of a ‘true’ carcinoma. This report is singular among 17th‐century case histories. The neoplasias described 300 years later are most probably biologically identical. Thus, Fabry’s is the first clinical report; the histological classification, however, belongs to Buschke and Löwenstein. From now on the disease should be designated with the eponym giant condyloma of Fabry–Buschke–Löwenstein or GCFBL.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here